Category Archives: Stem Cell Medical Center

How cancer cells grow and spread in colon tissue? – Tech Explorist

Scientists from the Duke University Medical Center have observed how stem cell mutations quietly emerge and spread all through a broadening field of the colon until they eventually prevail and become a malignancy.

Scientists tried an innovative modeling system called molecular dyeing technique on mice to visually tag colon cancer mutations by causing stem cells to glow. Mutations found in colon cancer were then envisioned in the animals, enlightening a kind of tournment-to-the-death underway in the intestine in which some mutation beat the others to turn into the main impetus of a malignancy.

Joshua Snyder, Ph.D., assistant professor in the departments of Surgery and Cell Biology at Duke and corresponding and co-senior author of a study, said, This study provides new insight into the previously invisible process in which mutant precancerous stem cells spread throughout the colon and seed cancer. Our technique sets a firm foundation for testing new therapies that interrupt this new, pre-malignant process. We hope to one day target and eliminate these stealth precancerous cells to prevent cancer.

The technique that was applied uniquely tagged several common colon cancer mutations in the stem cells of a single tumor to create a fluorescent barcode. When transferred to a mouse, the rainbow of fluorescent stem cells could be visually tracked, revealing the cellular and molecular dynamics of pre-cancerous events.

In this way, the researchers found key differences in how the intestinal habitats typical to babies and adults grow pre-cancerous fields of mutant cells. At a critical period, newborns are sensitive to the effects of mutations within intestinal stem cells.

This insidiously seeds large fields of premalignant mutated cells throughout the intestine a process called field cancerization that dramatically increases cancer risk. These fields of mutated cells can grow and spread for years without being detected by current screening technologies; often, they remain harmless, but under proper conditions, they can rapidly become cancerous later in adults.

Scientists also found that some mutations can cause a striking increase in the fertility of the environment surrounding precancerous fields. At last, this prompts the rapid spread of areas throughout the intestine, with lethal outcomes.

Specific common mutations that arise from external sources, such as an injury or an environmental exposure, could also disrupt the environment surrounding the stem cell and lead to the rapid growth and spread of precancerous fields. These occurrences can be especially lethal in adults and occur much more rapidly than previously expected as if dropping a match on a drought-stricken forest.

Synder said, Field cancerization has been suggested to be the defining event that initiates the process of cancer growth, including cancers of the breast, skin, and lung. Our technique allows us to model how premalignant cells compete and expand within a field by simple fluorescent imaging, potentially leading to earlier diagnosis and treatment.

Additional studies are underway using the fluorescent barcoding to view the cancer fields in breast cancer, aiming to learn more about when malignant vs. benign mutations drive a pre-cancerous condition known as ductal carcinoma in situ.

The study is published online in the journal Nature Communications.

Read this article:
How cancer cells grow and spread in colon tissue? - Tech Explorist

Hidden Dangers Of Dating Apps: Sex Offenders, Including Rapists, Are Using Them. Why Do Companies Allow It? – Kaiser Health News

A lack of a uniform policy allows convicted and accused perpetrators to access some dating apps and leaves users vulnerable to sexual assaults, according to an investigation. Public health news is on stem cell heart therapy, flu season, Parkinson's disease, poetry therapy, problems with blood-sugar monitors, warnings about ski helmets, a grateful transplant patient, children prone to violent outbursts, and more.

ProPublica:Tinder Lets Known Sex Offenders Use The App. Its Not The Only One.Susan Deveau saw Mark Papamechails online dating profile on PlentyofFish in late 2016. Scrolling through his pictures, she saw a 54-year-old man, balding and broad, dressed in a T-shirt. Papamechail lived near her home in a suburb of Boston and, like Deveau, was divorced. His dating app profile said he wanted to find someone to marry. Deveau had used dating websites for years, but she told her adult daughter the men she met were dorky. (Flynn, Cousins and Picciani, 12/2)

The Washington Post:Benefits Of Stem Cell Heart Therapy May Have Nothing To Do With Stem Cells, A Study On Mice SuggestsFor 15 years, scientists have put various stem cells into seriously ill patients hearts in hopes of regenerating injured muscle and boosting heart function. A new mouse study may finally debunk the idea behind the controversial procedure, showing the beneficial effects of two types of cell therapy are caused not by the rejuvenating properties of stem cells, but by the bodys wound-healing response which can also be triggered by injecting dead cells or a chemical into the heart. (Johnson, 11/27)

The Associated Press:Flu Season Takes Off Quickly In Deep South StatesThe flu season is off and running in the Deep South. The most recent weekly flu report from the Centers for Disease Control and Prevention finds high levels of flu-like illness in Alabama, Arkansas, Georgia, Nevada, South Carolina and Texas. The highest level in that report for the week ended Nov. 16 was in Mississippi. Doctors in the Magnolia State say theyre already seeing lots of patients. (11/29)

The New York Times:Swimmers Beware Of Deep Brain StimulationA lifelong swimmer leapt into deep water near his lakeside home, and was horrified to find himself completely unable to swim. Had his wife not rescued him, he might have drowned. He had recently received an electronic brain implant to control tremors and other symptoms of Parkinsons disease, and somehow the signals from the device had knocked out his ability to coordinate his arms and legs for swimming. (Grady, 11/27)

The Wall Street Journal:A Prescription Of Poetry To Help Patients Speak Their MindsDr. Joshua Hauser approached the bedside of his patient, treatment in hand. But it wasnt medicine he carried. It was a copy of a 19th-century poem titled Invictus. It isnt often that doctors do rounds with poetry. But Dr. Hauser, section chief of palliative care at the Jesse Brown VA Medical Center, and colleagues are testing it as part of a pilot study. He entered Mr. Askews room. The patient had asked for Invictus, a dark poem by William Ernest Henley that he remembered from his past. (Reddy, 12/1)

The Wall Street Journal:Diabetes Patients Blood-Sugar Data Arent Being SharedParents of young diabetes patients say they havent been getting crucial readings from blood-sugar monitors worn by their children since early Saturday. The technological breakdown, the origin of which isnt certain, threatens the proper care of the young diabetes patients. (Loftus, 12/1)

The New York Times:Study Warns Helmets Dont Offer Full Protection On SlopesCONCORD, N.H. For several years now, it has been almost de rigueur for skiers and snowboarders to strap on a helmet amid rising concerns about safety on the slopes. But a new study caution that helmets cannot protect skiers from all head injuries. (11/28)

Kaiser Health News:For Artist Inspired By Illness, Gratitude Outweighs PainPeople often ask Dylan Mortimer how it feels to breathe through transplanted lungs. He gets that a lot because while most people go through life with one pair of lungs, Mortimer is on his third. The 40-year-old artist has endured two double lung transplants in the past two years. He often shares his journey onstage as a speaker. But when the curtain closes, he leaves the rest of the storytelling to art. Im alive because of what someone else did, Mortimer said. That is humbling in all the best ways. (Anthony, 12/2)

NPR:Teens Who Threaten And Hit Their Parents: That's Domestic Violence TooNothing Jenn and Jason learned in parenting class prepared them for the challenges they've faced raising a child prone to violent outbursts. The couple are parents to two siblings whom they first fostered as toddlers and later adopted. In some ways, the family today seems like many others. Jenn and Jason's 12-year-old daughter is into pop star Taylor Swift and loves playing outside with her older brother. (Herman, 11/29)

NPR:Give Thanks For Adult Siblings And The Ties That BindWe didn't expect to need the card table for spillover seating at this year's Thanksgiving dinner. We would be fewer than usual, just nine altogether, and the littlest one's high chair needs no place setting. As we got things ready, I felt deep gratitude for the family members who would be here my husband, our two daughters, their husbands, my sister-in-law's 90-year-old mother and our two delightful granddaughters. But I also knew I would deeply miss the ones who couldn't make it. (Henig, 11/28)

The Washington Post:Doctors In China Found Tapeworms In Brain Of Man Who Ate Undercooked Meat In Hot PotA Chinese man sought medical attention for seizures and a headache that lasted nearly a month. Doctors found that tapeworms from undercooked meat were causing his pain. Researchers at the First Affiliated Hospital of Zhejiang University published a paper last week that details the plight of 46-year-old construction worker Zhu (an alias for the patient) in the eastern Zhejiang province of China who bought pork and mutton about a month ago for a spicy hot pot broth. (Beachum, 11/27)

Visit link:
Hidden Dangers Of Dating Apps: Sex Offenders, Including Rapists, Are Using Them. Why Do Companies Allow It? - Kaiser Health News

Cellex Opens New Plant to Manufacture Innovative Cell Therapy Products for Cancer – PRNewswire

COLOGNE, Germany, Dec. 5, 2019 /PRNewswire/ -- Cellex has opened a new Cell Manufacturing Plant in Cologne, Germany that will be the focal point for the production of innovative cell therapy products (e.g. CAR-T cells) as targeted treatments for different types of cancers and other diseases. The new facility has doubled the company's manufacturing capacity. Reasons for the expansion include the rising global demand and worldwide bottlenecks in production, as well as a considerable amount of promising research on new treatment approaches for various types of cancer. With this expansion, Cellex has laid the groundwork to provide comprehensive support to patients all over the world who are dependent on new therapies for the treatment of serious diseases. The facility offers more than 800 square meters of floor space and contains a clean room laboratory and other rooms for manufacturing and quality control.

At the new Cell Manufacturing Plant, advanced therapy medicinal products (ATMPs) such as CAR-T cells are produced using state-of-the-art methods including magnetic selection, cell purification, cryopreservation and cell-based efficacy tests. Other services include long-term cryo-storage for ATMPs. Through international partnerships, Cellex is already operating at a global level and is expecting to see growth in worldwide demand for its products. In addition to specialized expertise in manufacturing cell therapy products, the company also operates collection centers for stem cell and bone marrow donations as well as a CellCommunity for the donation of cells to science and research all over the world.

The Cellex Group was founded in 2001 with a primary focus on the collection of stem cells and bone marrow. Today, the Cellex Collection Center is the world's largest and most experienced collection center for allogeneic blood stem cell and bone marrow donations. Furthermore, Cellex has grown into an important full service provider for other companies in the production of innovative cellular therapy products (e.g. CAR-T cells). Since 2014, the company has been working on the development of its own innovative CAR-T cells and bispecific antibodies for the treatment of cancer in collaboration with its Dresden-based affiliate, GEMoaB.

During the opening ceremonies, Prof. Dr. Gerhard Ehninger, founder and owner of Cellex, pointed to the encouraging possibilities offered by CAR-T cell therapies being developed by Cellex. "Battling cancer with CAR-T cells specifically targeted against tumor cells is one of the most promising treatment approaches today. However, CAR-T cells developed so far harbor various risks, such as excessive cytokine release or the development of resistances. Therefore, we are now collaborating with our affiliate, GEMoaB, to develop new platforms that are easier to control such as bispecific antibodies or UniCAR cells, which are currently undergoing initial testing."

About Cellex

Cellex wants to help people suffering from serious diseases through stem cell donations, but also through innovative treatment options. Cellex develops, tests and establishes new therapy approaches for people with cancer. These new cutting-edge medicines are manufactured by Cellex at the company's Cell Manufacturing Plant.

The Cellex Collection Center is the largest and most experienced collection center for allogeneic blood stem cells and bone marrow in the world. More than 55 percent of all stem cell donations in Germany are collected by Cellex. In addition to the manufacturing of cell therapy products, Cellex is involved in research for new cell products and collaborates with a large number of other companies.

Media Contact

Julia Bose, Head of Marketing & CommunicationsTelephone: +49-221-4545-916E-mail: j.bose@cellex.me

SOURCE Cellex GmbH

Go here to read the rest:
Cellex Opens New Plant to Manufacture Innovative Cell Therapy Products for Cancer - PRNewswire

Analysis Shows Need for Better Classification of Rare Lymphoma – Patch.com

New Brunswick, N.J. - December 4, 2019 In what is believed to be one of the largest studies of a rare disorder known as primary cutaneous gamma delta T-cell lymphoma (PCGDTCL), Rutgers Cancer Institute of New Jersey investigators and other collaborators examined characteristics, treatment patterns and outcomes of the disease, and determined accurate diagnosis of the disease requires ongoing analysis. Results of the work are being shared as part of a poster presentation at the American Society of Hematology Annual Meeting in Orlando this week by lead investigator Kevin David, MD, hematologist/oncologist at Rutgers Cancer Institute. Dr. David, who is also an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, shares more about the work.

Q: Why is this topic important to explore?

A: Primary cutaneous gamma delta T-cell lymphoma is a rare disorder, and in comparison to other more common subtypes of non-Hodgkin lymphomas, relatively little is known about prognostic factors and optimal treatments. Although it is a rare condition, it can in many instances behave quite aggressively and profoundly impact patients. Therefore, learning more about how this disease behaves, which disease characteristics affect outcomes, and which treatments may improve outcomes are all important to understand more fully.

Q: Tell us about the work and what you and your colleagues found.

A: Given the rarity of this particular lymphoma, collaboration with lymphoma researchers across the country was key in this study. We identified cases of PCGDTCL at 10 U.S. medical centers that occurred between 2000 and 2017, and collected information about patient characteristics, pathology characteristics, treatments administered, and outcomes, including remission rates and the length of time the disease was controlled. Although it is ideal for lymphomas to be diagnosed with uniform standards across the country, we found important nuances in the manner in which pathologists at different medical centers diagnose this rare lymphoma. Identifying these differences will be key to better streamline diagnoses in the future. We also found that patients in better overall health, as measured by the ECOG Performance Status scale, and with normal, as opposed to increased, levels of a tumor marker (lactate dehydrogenase) had better outcomes.

There is no one standard treatment regimen for this lymphoma, and a wide variety of treatments were used for newly diagnosed patients, ranging from ultraviolet light treatment to multi-agent chemotherapy. While no single treatment regimen resulted in the best outcomes, our results suggest that incorporating allogeneic stem cell transplant in treatment planning can improve results.

Q: Why are these results significant?

A: Our findings demonstrate the importance of trying to create and adhere to more uniform diagnostic criteria for this rare lymphoma. Additionally, we have much work to do in identifying better treatment regimens to improve outcomes for PCGDTCL, and continued multi-center collaborations will be crucial.

Aside from David, other authors on the work are Melissa Pulitzer, MD, Memorial Sloan Kettering Cancer Center; Joan Guitart, MD, and Maria Estela Martinez-Escala, MD, both Northwestern University Feinberg School of Medicine; Sharmir Geller, MD and Yaqun Wang, both Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; N. Nora Bennani, MD and Kay M. Ristow, BS, both Mayo Clinic; Daniel J. Landsburg, MD Abramson Cancer Center; Nicole Winchell and Paul Haun, MD, both University of Pennsylvania; Pamela Allen, MD, MSc, Emory University Winship Cancer Institute; Basem M. William, MRCP, MD, The Ohio State University James Comprehensive Cancer Center; Nathan Denlinger, MS, DO, Ohio State University Exner Medical Center; Neha Mehta-Shah, MD, Washington University; Ryan A. Wilcox, MD, PhD, University of Michigan Cancer Center; Alexandra Hristov, University of Michigan; Tatyana A. Feldman, MD and Alex Weller, Hackensack University Medical Center, New Jersey; Andrew M. Evens, DO, MSc, Rutgers Cancer Institute and Steven M. Horowitz, MD Memorial Sloan Kettering Cancer Center. Author disclosures and other details can be found here: https://ash.confex.com/ash/2019/webprogram/Paper130223.html.

###

Continued here:
Analysis Shows Need for Better Classification of Rare Lymphoma - Patch.com

Aledo and Ennis will be a legendary regional final matchup, and not because of what’s on the playing field – The Dallas Morning News

Aledo head coach Tim Buchanan was asked, moments after last Fridays 34-14 win over Red Oak, about how excited he was to get to the regional final.

The Bearcats coach flashed a smile and then started laughing once he realized who hed be facing in the regional final.

Now we get to play a damn legend in Sam Harrell, Buchanan said.

Harrell is the head coach at Ennis, which shut out Frisco 17-0 in the regional semifinals to advance to face Aledo, the reigning 5A-II state champions. The two teams play Friday at 7:30 p.m. at the Ford Center at The Star in Frisco.

On the field, it figures to be a quality matchup. Ennis, with only one loss to its name, is averaging 33.5 points per game while allowing 13.5. Aledo, on the other hand, is averaging 53.8 points per game while allowing just under 17. Its only loss was a three-point defeat to 6As Denton Guyer, which is also playing in a regional final this weekend.

The matchup on the sidelines, however, may be more interesting. Buchanan and Harrell are both in their second tenures at their respective schools.

Buchanan (239-52-3) is known as the architect of Aledos dynasty. He won five state championships as the schools head coach before he moved full-time into the districts athletic director position after the 2013 season. Once he turned in his whistle, he said he missed it. So, when the possibility of returning to the sideline became available this offseason, he jumped, swapping places with former Aledo head coach Steve Wood.

Harrell (206-65) is in his second season back at Ennis. The former Big Lake head coach took over at Ennis in 1994, leading the Lions to three state championships in the early 2000s. Multiple sclerosis forced him to retire after the 2009 season, but after stem cell treatment and a couple of trips to Panama, he ultimately made it back to the sidelines. He took Ennis back over in 2018, and after a 5-5 season a year ago, Harrell has the Lions back on the precipice of playoff glory.

Eight state championships and 445 wins isnt a bad combination for two head coaches facing off against each other in the regional final. Some may call it legendary. At least thats what Buchanan says about Harrell.

Ive never beat Sam, Buchanan said, adding that the two have known each other for a long time, so that will be fun, getting to play Coach Harrell again.

See the original post:
Aledo and Ennis will be a legendary regional final matchup, and not because of what's on the playing field - The Dallas Morning News

Volumetric Bioprinting: The New Paradigm in Regenerative Medicine – Advanced Science News

Share

Share

Email

Creating an object from a scratch: not just an illusion, but a reality. Nowadays, there is a way to turn your ideas into three-dimensional objects and here, the magic word is 3D printing.

This technique, also called additive manufacturing, consistsofn successive layer-by-layer depositions of material which, all together, form the desired object. Contrary to conventional techniques, 3D printing allows the manufacturing of complex shapes using a small amount of material and reduced number of fabrication steps.

With the term 3D printing, we usually refer to technologies which use polymers, resins and molten metals as printing material to produce three-dimensional objects. However, over the last 30 years, this concept has developed toward new horizons, leading to the production of 3D artificial bio tissues which resemble the architecture and function of native ones. In this case, when used to deposit living cells layer-by-layer, we talk more specifically about 3D bioprinting.

Nowadays, the most common technologies for 3D bioprinting are based on approaches such as extrusion printing, stereolithography, laser-based methods, and melt electrowriting. These technologies have the ability to accurately control the spatial orchestration of multiple cell types and biomaterials in an automated patterning process. However, they also present some disadvantages, e.g., the difficulties in reproducing convoluted geometries, which in fact are typical of native tissues. Moreover, a severe restriction is represented by long printing times when large, physiological-sized constructs need to be fabricated. This characteristic also affects the large-scale production of artificial tissues, thus limiting the adoption of 3D bioprinting at an industrial level.

In order to overcome these limitations, Prof. Riccardo Levato of the University Medical Center Utrecht, the Netherlands, and Prof. Christophe Moser of cole Polytechnique Fdral Lausanne (EPFL), Switzerland, have proposed a new strategy for the 3D bioprinting. In their recently published article they present a Volumetric Bioprinting (VBP) approach to create any convoluted free-form geometry with unprecedented speed of fabrication.

This method takes inspiration from the principle of computed tomographycommonly used in medical imagingalthough in reverse. In VBP, a cell-friendly visible laser light is used to cast multiple tomographic projections onto a light-sensitive hydrogel embedding stem cells.Although the whole volume is photo-exposed, the composition of these projections creates a 3D light field that provides enough energy to crosslink the hydrogel only in correspondence to the desired design. This results in a 3D construct, floating in the host hydrogel, which can be realized in the time frame of a few tens of seconds.

Contrary to other bioprinting technologies, e.g., stereolithography, which works in the time scale of hours to produce clinically-relevant sized (> cm3) structures, VBP thus permits the fabrication of living tissue constructs with analogous dimensions and complex 3D architectures by strongly reducing the fabrication times. As a consequence, VBP not only leads to high mimicry of the architecture of human tissues, but it preserves cells by minimizing the time outside of their optimal culture environment.

Given the freedom to print any complex geometry, anatomical, patient-specific grafts with unprecedented precision and short fabrications times, VBP lends itself to be the new paradigm of regenerative medicine, also paving the way for the scaling-up of tissue production. Thanks to these characteristics, Prof. Levato and Prof. Moser expect this approach will find application in many fields also outside tissue engineering, even including soft robotics. As they claimed, We expect Volumetric Bioprinting technology to be part of the bioprinting toolkit that will one day create fully functional organs.

In the future, the authors aim to further improve VBP technology by addressing the structural function of load bearing tissues, developing new materials and fully matching the function between their biofabricated tissues and the native ones. This sounds promising to us: we are looking forward to seeing new developments!

More here:
Volumetric Bioprinting: The New Paradigm in Regenerative Medicine - Advanced Science News

Heres what you might have missed from the week in business – The Boston Globe

PRIYANKA DAYAL MCCLUSKEY

A group of leading Boston-area universities, hospitals, and corporations will create a new center for bio-manufacturing and innovation in or near the city, Harvard University said Monday, and hopes to have the facility up and running by 2022 or even 2021 in an effort to protect the areas leadership in the life sciences. That leadership is threatened by severe bottlenecks in bio-manufacturing, said Harvard officials, who spent two years canvassing experts on what Massachusetts needs to do to keep promoting biotech in both academia and industry. Bio-manufacturing refers to growing vast quantities of human cells, including genetically engineered ones and those produced from stem cells; strands of genetic material that can be used to treat diseases; and other biological molecules. A bio-manufacturing facility opened at Dana-Farber Cancer Institute in 2018, but the $35 million, 30,000-square-foot cell-manufacturing space became oversubscribed almost immediately. Dana-Farber is among the initial partners in the planned facility, for which the organizers have $50 million in commitments to cover design, construction, and early operation. The others include, besides Harvard, the Massachusetts Institute of Technology, Fujifilm Diosynth Biotechnologies, GE Healthcare Life Science, Alexandria Real Estate Equities, Beth Israel Deaconess Medical Center, Boston Childrens Hospital, Brigham and Womens Hospital, and Massachusetts General Hospital.

SHARON BEGLEY, STAT

One of the business pioneers of the Seaport District appears ready to grow in a new corner of the burgeoning neighborhood. Vertex Pharmaceuticals is poised to lease a building under construction in the Raymond L. Flynn Marine Industrial Park, the biotechnology company said this week. A lease has not been finalized, but Vertex and development firm Related Beal are in advanced talks for 256,000 square feet of space at Innovation Square, a lab and office project Related is building on Tide Street. Vertex would use it as a research and manufacturing facility for genetic and cellular therapies, a key part of the companys push into treatments for diseases beyond cystic fibrosis, which has long been its main focus. Earlier this year, the drug maker bought Watertown-based Exonics, which is developing gene therapies for Duchenne muscular dystrophy, and Semma Therapeutics, which is working on medicines for type 1 diabetes. Vertex also is moving forward in clinical trials of gene editing treatments.

TIM LOGAN

The company that owns the A.C. Moore chain of arts supply stores is leaving the industry and is planning to shut down all of its estimated 145 stores, which includes 12 in Eastern Massachusetts and on Cape Cod. At the same time that Nicole Crafts announced its departure plans, it also said the operator of the Michaels chain of arts and crafts stores will assume the leases in as many as 40 current A.C. Moore locations. The companies did not immediately lay out a timetable for the A.C. Moore closures, nor did Michaels identify the stores it will be taking over, remodeling, and then reopening next year. Nicole Crafts chief executive Anthony Piperno said in a statement that the stores will remain open for the time being, but the company will no longer accept online orders as of Monday.

JOHN R. ELLEMENT

The path is now clear for mobile sports betting to begin in New Hampshire in January. The New Hampshire Executive Council approved a contract on Monday between Boston-based DraftKings and the New Hampshire Lottery. A deal in the future with another sports betting operator such as FanDuel is not out of the question, but DraftKings emerged as the winner of a competitive bidding process in which New Hampshire preferred DraftKings app, implementation timeline, and the 51 percent gaming revenues it will hand over to the state. In the spring, municipalities will decide whether or not to open physical sports books in their towns. New Hampshire sports bettors will have to be 18 years or older, and they will not be permitted to bet on New Hampshire college teams or on any college games being played in New Hampshire. DraftKings will open an office in the Granite State.

MICHAEL SILVERMAN

For Belmont-raised Margaret Low, its a doubly sweet homecoming. WBUR-FM said Monday that the former NPR executive, who most recently ran The Atlantics events business, would take over in mid-January as its CEO and general manager. Its a high-profile hire for the Boston radio station after a period of turmoil. Low, 61, has spent much of her career in Washington, D.C. Now she is returning to the region she moved away from shortly after college, and to the public radio world she left in 2014 after a 25-year stint with NPR. WBUR said that Lows extensive news skills combined with business success at The Atlantic magazines events division made her the ideal choice to lead the station as it confronts challenges in the fast-moving media industry. Low also will have to manage the stations sometimes contentious relationship with Boston University, which owns WBURs broadcast license and whose decisions have at times frustrated management and staff. Her hiring comes eight months after WBUR parted ways with general manager Charlie Kravetz, who significantly expanded the station during his eight years at the helm, including its move into podcasting and the opening of CitySpace, its local programming venue. Kravetz was highly regarded but took a hit for his handling of Tom Ashbrook, who was forced out as host of the nationally syndicated show On Point after a review found he had created a hostile work environment. Kravetzs departure followed a February vote by about 100 workers to unionize amid complaints about the work environment.

LARRY EDELMAN

Continued here:
Heres what you might have missed from the week in business - The Boston Globe

Genome Editing Services, World Markets to 2030: Focus on CRISPR – The Most Popular Genome Manipulation Technology Tool – PRNewswire

DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Genome Editing Services Market-Focus on CRISPR 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions.

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology.

Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers.

Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve/augment existing gene editing tools, especially the CRISPR-based genome editing processes.

Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

Report Scope

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.

In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world).

To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. Overview of Genome Editing3.3. History of Genome Editing3.4. Applications of Genome Editing3.5. Genome Editing Techniques3.5.1. Mutagenesis3.5.2 Conventional Homologous Recombination3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)3.5.5. Protein-based Nuclease Systems3.5.5.1. Meganucleases3.5.5.2. Zinc Finger Nucleases3.5.5.3. Transcription Activator-like Effector Nucleases3.5.6. DNA Guided Systems3.5.6.1. Peptide Nucleic Acids3.5.6.2. Triplex Forming Oligonucleotides3.5.6.3. Structure Guided Endonucleases3.5.7. RNA Guided Systems3.5.7.1. CRISPR-Cas93.5.7.2. Targetrons3.6. CRISPR-based Genome Editing3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria3.6.2. Key CRISPR-Cas Systems3.6.3. Components of CRISPR-Cas System3.6.4. Protocol for CRISPR-based Genome Editing3.7. Applications of CRISPR3.7.1. Development of Therapeutic Interventions3.7.2. Augmentation of Artificial Fertilization Techniques3.7.3. Development of Genetically Modified Organisms3.7.4. Production of Biofuels3.7.5. Other Bioengineering Applications3.8. Key Challenges and Future Perspectives

4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape4.2.3. Analysis by Type of Service Offering4.2.4. Analysis by Type of gRNA Format4.2.5. Analysis by Type of Endonuclease4.2.6. Analysis by Type of Cas9 Format4.2.7. Analysis by Type of Cell Line Engineering Offering4.2.8. Analysis by Type of Animal Model Generation Offering4.2.9. Analysis by Availability of CRISPR Libraries4.2.10. Analysis by Year of Establishment4.2.11. Analysis by Company Size4.2.12. Analysis by Geographical Location4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. COMPANY PROFILES6.1. Chapter Overview6.2. Applied StemCell6.2.1. Company Overview6.2.2. Service Portfolio6.2.3. Recent Developments and Future Outlook6.3. BioCat6.4. Biotools6.5. Charles River Laboratories6.6. Cobo Scientific6.7. Creative Biogene6.8. Cyagen Biosciences6.9. GeneCopoeia6.10. Horizon Discovery6.11. NemaMetrix6.12. Synbio Technologies6.13. Thermo Fisher Scientific

7. PATENT ANALYSIS7.1. Chapter Overview7.2. Scope and Methodology7.3. CRISPR-based Genome Editing: Patent Analysis7.3.1. Analysis by Application Year and Publication Year7.3.2. Analysis by Geography7.3.3. Analysis by CPC Symbols7.3.4. Emerging Focus Areas7.3.5. Leading Players: Analysis by Number of Patents7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis7.4.1. Analysis by Patent Characteristics7.5. Patent Valuation Analysis

8. ACADEMIC GRANT ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. Grants Awarded by the National Institutes of Health for CRISPR-based8.3.1. Year-wise Trend of Grant Award8.3.2. Analysis by Amount Awarded8.3.3. Analysis by Administering Institutes8.3.4. Analysis by Support Period8.3.5. Analysis by Funding Mechanism8.3.6. Analysis by Type of Grant Application8.3.7. Analysis by Grant Activity8.3.8. Analysis by Recipient Organization8.3.9. Regional Distribution of Grant Recipient Organization8.3.10. Prominent Project Leaders: Analysis by Number of Grants8.3.11. Emerging Focus Areas8.3.12. Grant Attractiveness Analysis

9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES/SYSTEMS AND TOOLS9.1. Chapter Overview9.2. CRISPR-based Technology Providers9.2.1. Analysis by Year of Establishment and Company Size9.2.2. Analysis by Geographical Location and Company Expertise9.2.3. Analysis by Focus Area9.2.4. Key Technology Providers: Company Snapshots9.2.4.1. APSIS Therapeutics9.2.4.2. Beam Therapeutics9.2.4.3. CRISPR Therapeutics9.2.4.4. Editas Medicine9.2.4.5. Intellia Therapeutics9.2.4.6. Jenthera Therapeutics9.2.4.7. KSQ Therapeutics9.2.4.8. Locus Biosciences9.2.4.9. Refuge Biotechnologies9.2.4.10. Repare Therapeutics9.2.4.11. SNIPR BIOME9.2.5. Key Technology Providers: Summary of Venture Capital Investments9.3. List of CRISPR Kit Providers9.4. List of CRISPR Design Tool Providers

10. POTENTIAL STRATEGIC PARTNERS10.1. Chapter Overview10.2. Scope and Methodology10.3. Potential Strategic Partners for Genome Editing Service Providers10.3.1. Key Industry Partners10.3.1.1. Most Likely Partners10.3.1.2. Likely Partners10.3.1.3. Less Likely Partners10.3.2. Key Non-Industry/Academic Partners10.3.2.1. Most Likely Partners10.3.2.2. Likely Partners10.3.2.3. Less Likely Partners

11. MARKET FORECAST11.1. Chapter Overview11.2. Forecast Methodology and Key Assumptions11.3. Overall CRISPR-based Genome Editing Services Market, 2019-203011.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-203011.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-203011.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-203011.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-203011.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-203011.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-203011.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-203011.5.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-203011.5.3. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-203011.6. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-203011.6.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-203011.6.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-203011.6.3. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030

12. SWOT ANALYSIS12.1. Chapter Overview12.2. SWOT Analysis12.2.1. Strengths12.2.2. Weaknesses12.2.3. Opportunities12.2.4. Threats12.2.5. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/78rwbq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the rest here:
Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - PRNewswire

The FutureAnd the End?of AIDS – Columbia University Irving Medical Center

Throughout much of the world, a diagnosis of HIV/AIDS that once meant a certain death sentence now means living with a chronic, controllable disease. If you think about the fact that this epidemic was only recognized in 1981, the progress has been enormous, says David Ho, MD, the AIDS pioneer who was recruited to VP&S this year as the Clyde56 and Helen Wu Professor of Medicine. We do not have a vaccine. We do not have a cure. But we have turned a deadly disease into a manageable condition.

Ho has witnessed that transformation firsthand. He saw some of the earliest AIDS cases in the United States as a resident at Cedars-Sinai Medical Center in Los Angeles in 1980. I will always remember the young man who came to the hospital with a multitude of infections, he recalls of his first case. He was treated but, nevertheless, died within a few weeks after leaving the hospital.

Soon, another young man with pneumonia and other infections came to the hospital, was treated, and, again, died very quickly. It was this second, then third case, that began to raise alarm, says Ho. Within a year, those patients were included in the first case report submitted to the Centers for Disease Control and Prevention on what would become known as the AIDS epidemic.

What he saw in the clinic moved Ho to pursue HIV research throughout the 1980s. His renown grew, and by 1990 Ho had been named scientific director and chief executive officer of the Aaron Diamond AIDS Research Center, or ADARC, the largest independent nonprofit organization dedicated to basic research in HIV/AIDS. In 2019, ADARC moved to Columbia University Irving Medical Center.

Ho's work has played a key role in what is now known about HIV. He helped elucidate the nature of HIV replication, developed a number of antiretroviral drugs, and at the 1996 International AIDS Conference presented his teams breakthrough study results that proved combination therapy could reduce HIV viral loads to undetectable levels for at least one year. That was a turning point in the treatment efforts, says Ho.

Much of ADARCs research focuses on antibodies to prevent HIV transmission. One antibody in particular, engineered by ADARC six years ago, obstructs viral entry into the host cell. It turns out to be extremely powerful in blocking HIV infection in the lab and in laboratory animals, says Ho. He and his team have initiated a year-long, phase 1 trial of the antibody in infected patients and healthy volunteers. The trial is also being conducted at Columbia, led by Magdalena Sobieszczyk, MD, chief of the infectious diseases division.

If all goes well in this and subsequent human trials, Ho foresees the antibody being delivered every few months by subcutaneous injection to protect against HIV infection, much like a long-acting contraceptive prevents pregnancy.

Hos antibody research is one vital endeavor amid a broader and urgent effort to prevent new HIV infections worldwide, and ADARC is joining existing Columbia research programs with the same goal. The goal announced by the U.S. president in early 2019to end AIDS including decreasing the number of new HIV infections by 90% by 2030 in the United Statesis a bold one, notes University Professor and global director for ICAP at Columbia University Wafaa El-Sadr, MD. While there has been a huge scale-up in terms of treatment domestically and globally, we are not on track to reach the goal of HIV prevention in terms of the number of new infections. More than a million are still reported globally every year.

In May, the New England Journal of Medicine published a perspective on the 2030 target by El-Sadr and coauthored by Miriam Rabkin, MD, associate professor of medicine and of epidemiology (in Columbias ICAP) with colleagues at the Fenway Institute and the University of West Virginia. HIV affects the most vulnerable among us, they noted, highlighting the disproportionate number of new cases among people of color, transgender people, people in rural areas who use injectable drugs such as opioids, and those most affected by poverty and unstable housing.

The medical community already has the tools to overcome these challenges, says El-Sadr, who is co-principal investigator of the NIH-funded HIV Prevention Trials Network, or HPTN. In 2016, an HPTN study confirmed that HIV treatment is, itself, a highly effective form of prevention. When you treat people living with HIV, she says, not only does the person being treated benefit, but you also decrease the risk of transmission of HIV to others. Thus, the scale-up of HIV treatment has been a fundamental global priority championed as well by ICAP in the countries where it works.

For individuals who are HIV-negative, several preventive options are now available. An important one is pre-exposure prophylaxis, or PrEP, an approach where persons can protect themselves by taking a daily pill. Post-exposure prophylaxis, on the other hand, offers protection by taking medications after a suspected sexual or occupational exposure to prevent infection.

As co-PI of HPTN, El-Sadr designs and implements HIV prevention research across the United States and in Latin America, Africa, and Asia. Our goal is to design the best possible research to identify new prevention tools and determine how to use them. Then, importantly, we need to get what we know works to the people who need it so we can demonstrate the benefits at a population level. The same values infuse ICAP, the Columbia-based global health center that El-Sadr founded in 2003 to develop and deliver comprehensive, family-focused HIV services and evidence-based initiatives to bolster national health systems.

Despite more positive attitudes toward people living with HIV, El-Sadr notes that stigma still impedes testing, status disclosures, and access to prevention and treatment among many people in high-risk populations. Keep in mind that some of these same populations, even without HIV, are stigmatized, she says. If you are a young man having sex with men in a Southern rural community in the United States, if you are a transgender woman, even in New York City, your whole outlook on life is shaped by prevailing stigma and discrimination. Adding HIV makes it doubly difficult in so many ways.

To fight back, El-Sadr marshals creativity and engagement. Many of the ICAP-led projects she has created train and empower peer educators to share their own experiences, talk about how they overcame similar challenges, and encourage others to participate in research studies as well as programs. That approach has been the backbone of her work since the late 1980s, when she established the first HIV research unit at Harlem Hospital. Peer educators are from the same communities as those we seek to serve. They know what is going to resonate. They also know how to model behaviors. They have been a huge part of our work, whether it be in Tanzania, Swaziland, Kazakhstan, or right here in New York.

Outreach has been central to the peer educators roles, says El Sadr. For example, in Tanzania, the ICAP-supported teams work to reach those most disenfranchised, going wherever they are needed and doing whatever is needed. They organize festive campaigns in village centers, visit artisanal miners, brothels, drug dens, fishing villages where the population is transient. Carrying backpacks loaded with supplies, peer educators talk to people, gain their trust, set up mobile units and tents, or do whatever is needed to get them the prevention and treatment they need. If you get out of the comfort zone of health facilities, clinics, hospitals, or research labs, get creative and collaborative, and sit with the people, listen to their concerns, speak in their language and offer them prevention, offer them treatment, right where theyneed it, guess what? They are quite willing to engage.

With nearly four decades of experience in the field, El-Sadr counsels diligence to achieve the ambitious U.S. HIV goals. First, she says, adequate funding is critically important. Second, the affected communities must be fully engaged. Third, resources and actions must be focused on the populations and locations where they are needed, informed by evidence and data. And finally, hard science must drive policy. We need to do what is supported by evidence, she says. There should be no room for political expediency.

Ho takes a cautiously optimistic stance on the 2030 target. It is possible, but a daunting task, he says. It requires political leadership, political will, and making sure that resources are properly given to the effort.

Over the past decade, ADARC has received nearly $50 million collectively from the Gates Foundation and the NIH to advance its research, with more to come. I think we could move the work we are doing with antibodies into the clinic and into at-risk communities to block HIV transmission even more effectively, says Ho. And I believe over the next five or 10 years, we are going to see tremendous progress in preventing HIV infection, not just with drugs like PrEP, but with antibodies and perhaps even with vaccines.

Decades of innovations, action, and partnerships have ushered in a new era in the global HIV responseone that could mean the end of AIDS. We are at a moment in history where we know enough to stem this epidemic, and we need to take what we know into action, says El-Sadr. At the same time, we must continue to seek new discoveries through research in the laboratory, in the clinic, and in the community. Both discovery and action are needed as we move forward.

Read the original here:
The FutureAnd the End?of AIDS - Columbia University Irving Medical Center

Visiongain Report Looks at Opportunities within the $1.8bn Acute Myeloid Leukaemia Market – P&T Community

- Global Acute Myeloid Leukaemia Market Forecast to 2029

- Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib

LONDON, Nov. 28, 2019 /PRNewswire/ -- The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13% in the first half of the forecast period. In 2018, the chemotherapy segment held 32% share of the global acute myeloid leukaemia market.

How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 149-page report you will receive 143 charts all unavailable elsewhere.

The 149-page Visiongain report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-acute-myeloid-leukaemia-market-forecast-to-2029/#download_sampe_div

Report Scope

Global Acute Myeloid Leukaemia Market forecast to 2029

Forecast of the Global Acute Myeloid Leukaemia market byTreatment Type and Product Type: Chemotherapy: Cytarabine, Daunorubicin, Others Targeted Therapy: Midostaurin, Enasidenib, Others

This report provides individual revenue forecasts to 2029 for these regional andnational markets: North America: US, Canada, and Mexico Europe: Germany, France, United Kingdom, Italy, Spain and rest of Europe Asia-Pacific: Japan, China, India, Australia and Rest of Asia-Pacific LAMEA: GCC, Brazil, South Africa, Rest of LAMEA

Each national market forecast is further segmented by type: chemotherapy and targeted therapy.

Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market: Bristol-Myers Squibb Company Celgene Clavis Pharma ASA Daiichi Sankyo Eisai GSK Novartis Roche Sunesis Pharmaceuticals Teva

This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.

This report discussesPorter's Five Forces analysis of the acute myeloid leukaemia market.

This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.

Key questions answered in this report: How is the Acute myeloid leukemia market evolving? What are the drivers and restraints for the growth of the acute myeloid leukemia market? What are the market shares of each segment of the overall acute myeloid leukemia market in 2019? How will each acute myeloid leukemia submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029? How will the market shares for each acute myeloid leukemia submarket develop from 2019 to 2029? What is the value of the leading acute myeloid leukemia segments in important regions of the world? What will be the main driver for the overall market from 2019 to 2029? How will political and regulatory factors influence the regional markets and submarkets? How will the market shares of the national markets change by 2029 and which geographical region will lead the market by 2029? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2019 and 2029?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-acute-myeloid-leukaemia-market-forecast-to-2029/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

AbbVieAgios Pharmaceuticals, Inc.Ambit Biosciences CorporationAmgenAnimas CorporationAstexB. Braun Melsungen AGBaxter, Becton, Dickinson and Company (BD)BayerBoehringer IngelheimBristol-Myers Squibb Company (Bristol-Myers)Celator Pharmaceuticals, Inc.CelgeneClavis Pharma ASA (Clavis Pharma)CyclacelDaiichi PharmaceuticalDaiichi SankyoEisai Co., Ltd. (Eisai)F. Hoffmann-La Roche Ltd. (Roche)Fresenius SE & Co. KGaAGlaxoSmithKline plc (GSK)GLOBOCANHospiraMedtronicMoog Inc.NeoMedNorsk HydroNovartisOnyx PharmaceuticalsSankyoSeattle GeneticsSmiths Group Plc.,Sunesis Pharmaceuticals, Inc. (Sunesis)TEVA Pharmaceutical Industries Limited (TEVA)

List of Organizations Mentioned in the ReportAmerican Cancer OrganizationBaylor Scott and White Research InstituteBenaroya Research Institute at Virginia MasonBeth Israel Deaconess Medical CenterBreslin Cancer CenterCenter for Blood Disorders and Stem Cell TransplantationCharles A. Sammons Cancer CenterColumbia University MedicalDana Farber Cancer InstituteDuke Cancer CenterEuropean CommissionFred Hutchinson Cancer Research CenterHealth CanadaHerbert Irving Comprehensive Cancer CenterInstitute of Hematology & Blood Diseases Hospital,TianjinJames Graham Brown Cancer CenterLegacy Emanuel Hospital & Health CenterMary Babb Randolph Cancer CenterMassachusetts general HospitalMayo ClinicMD Anderson Cancer CenterMedical College of Wisconsin Cancer CenterMedizinische Klinik und Poliklinik IMemorial Sloan Kettering Cancer CenterMichigan State UniversityNantes University HospitalNational Cancer InstituteNew Jersey Hematology Oncology AssociatesNorthwestern UniversityOchsner Medical CenterPenn State Hershey Cancer Institute-Clinical Trials OfficePerelman Center for Advanced MedicinePrincess Margaret HospitalSt. Francis Cancer CenterSt. Joseph Mercy HospitalSt. Vincent's Comprehensive Cancer CenterSwedish Cancer InstituteThe Gayle and Tom Benson Cancer CenterThe University of Hong KongThe University of IowaThe University of Texas MD Anderson Cancer CenterThomas Jefferson UniversityU.S. Food and Drug Administration (FDA)UCLA Medical Center, Division of Hematology/OncologyUniversity Hospital, CaenUniversity of Kansas Cancer CenterUniversity of Kansas Medical Center Research InstituteUniversity of KentuckyUniversity of LouisvilleUniversity of Michigan Health SystemUniversity of PennsylvaniaUniversity of Texas M.D. Anderson Cancer CenterVA Caribbean Healthcare SystemWeill Cornell Medical CollegeWeill Medical College of Cornell UniversityWest Virginia UniversityWorld Health Organization (WHO)

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Biosimilars and Follow-On Biologics Market 2019-2029

Global Protein Expression Market Forecast to 2029

Top 25 Biosimilar Drug Manufacturers 2019

Global Diagnostic Imaging Market Forecast 2019-2029

Global Oncology Pricing, Reimbursement & Market Access 2019-2029

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

Excerpt from:
Visiongain Report Looks at Opportunities within the $1.8bn Acute Myeloid Leukaemia Market - P&T Community